As of 2026-08-24, AEON Biopharma, Inc. (AEON) has a 3-month relative strength percentile of 3 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 25. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 11.8%, relative volume 0.45×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
AEON is in a stage 4 downtrend, week 5. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -53.5% / -76.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
AEON appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $89K notional.
Held by 1 ETFs · $89K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $89K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AEON Jan avg: -23.52% median: 0.14% win: 67% σ: 45.67% n: 3 2023-07-25 → 2026-07-31 | AEON Feb avg: -10.10% median: -3.45% win: 33% σ: 78.69% n: 3 2023-07-25 → 2026-07-31 | AEON Mar avg: -12.44% median: -12.05% win: 0% σ: 10.11% n: 3 2023-07-25 → 2026-07-31 | AEON Apr avg: -32.80% median: -25.28% win: 0% σ: 30.95% n: 3 2023-07-25 → 2026-07-31 | AEON May avg: -14.65% median: -18.02% win: 33% σ: 46.09% n: 3 2023-07-25 → 2026-07-31 | AEON Jun avg: -2.18% median: -4.94% win: 33% σ: 32.83% n: 3 2023-07-25 → 2026-07-31 | AEON Jul avg: -3.61% median: -9.49% win: 25% σ: 50.88% n: 4 2023-07-25 → 2026-07-31 | AEON Aug avg: -27.64% median: -31.97% win: 33% σ: 26.34% n: 3 2023-07-25 → 2026-07-31 (current) | AEON Sep avg: 13.78% median: 10.51% win: 100% σ: 10.93% n: 3 2023-07-25 → 2026-07-31 | AEON Oct avg: -4.39% median: -5.71% win: 33% σ: 8.92% n: 3 2023-07-25 → 2026-07-31 | AEON Nov avg: -11.11% median: -0.35% win: 33% σ: 25.99% n: 3 2023-07-25 → 2026-07-31 | AEON Dec avg: 18.56% median: 26.54% win: 67% σ: 16.78% n: 3 2023-07-25 → 2026-07-31 |